Depemokimab for adults with COPD and type 2 inflammation
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new biologic medicine called depemokimab, given as an injection, to see if it reduces flare-ups (exacerbations) in people with COPD who have a specific type of inflammation (high eosinophils). It may help if you have frequent flare-ups despite using your regular inhalers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have moderate to severe COPD and have had at least 2 moderate or 1 severe flare-up in the last year.
- Your blood test shows a high eosinophil count (type 2 inflammation).
- You are a current or former smoker with at least a 10 pack-year smoking history (e.g., 1 pack a day for 10 years).
- You have been using a combination of three types of inhalers (ICS, LAMA, LABA) for at least 6 months.
- You do not have asthma or other major lung diseases that could explain your symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
This study tests a new biologic medicine, given as an injection, to see if it can reduce flare-ups in adults with COPD who have a certain type of inflammation. It may help people who still have frequent exacerbations despite using their current inhalers.
This study tests a new medicine called depemokimab, given as an injection, to see if it can reduce asthma attacks in people with a specific type of asthma (type 2 high). If you have had asthma for several years and have had recent attacks despite using regular inhalers, this trial might be an option for you.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This study looks at how well a new injectable medicine called depemokimab works for people who have both allergic bronchopulmonary aspergillosis (ABPA) and severe eosinophilic asthma. It aims to see if this medication helps control symptoms and reduce the need for steroids.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.